I think we had a similar discussion a year or two ago around Replagal/Fabrazyme in EU. My memory isn't as good as others here so I don't recall your explanation of how both got approved there (whereas in the US Replagal was blocked by Orphan drug exclusivity)
Market Data 
Markets 
AI
